• Coherus Oncology schedules virtual annual stockholder meeting for May 27, 2026.
• Ballot includes election of two Class III directors with terms running to 2029.
• Shareholders will vote on advisory approval of named executive officer compensation.
• Company seeks approval to reprice certain outstanding employee and consultant stock options with exercise prices of $5 or more.
• Meeting also covers proposal to add 7,700,000 shares to 2014 equity incentive plan reserve.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-041578), on April 09, 2026, and is solely responsible for the information contained therein.